- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00396006
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)
April 17, 2021 updated by: Baxalta now part of Shire
The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)
The purpose of this study is to evaluate the effects of weekly augmentation therapy with ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor levels and other ELF analytes and to assess the safety of the treatment.
Eligible subjects with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8 consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered intravenously.
The efficacy and safety assessments will include two bronchoscopies with bronchoalveolar lavage on study initiation and on study termination and multiple imaging and laboratory safety assessments.
Each subject will participate for a minimum of 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia
-
-
Victoria
-
Melbourne, Victoria, Australia
-
-
Western Australia
-
Nedlands, Western Australia, Australia
-
-
-
-
-
Hamilton, New Zealand
-
-
Auckland
-
Otahuhu, Auckland, New Zealand
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent.
- Male or female 18 years of age or older.
- Documented, endogenous serum α1-PI level < 40 mg/dL measured at screening (unless otherwise approved by the Sponsor) after a minimum of 28-day washout of any prior replacement therapy (if applicable).
- Phenotype Pi Z (which includes Pi*Z/Z, Pi*Z/Null, or Pi*Malton/Z), or Pi*Null/Null.
Pulmonary functions at screening meeting the following criteria:
- Forced expiratory volume at 1 second (FEV1) >= 50% of predicted value; or
- FEV1 > 35% of predicted value and diffusing capacity for carbon monoxide > 45% of predicated value, with no supplemental oxygen therapy and < 3 pulmonary exacerbations or bronchitis requiring antibiotics/corticosteroids within the past 12 months).
- For any female of childbearing potential, a negative urine test for pregnancy within 7 days prior to the first bronchoalveolar lavage (BAL) visit and agreement to employ adequate birth control measures for the duration of the study.
- No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the screening visit (ECG previously obtained within the past 12 months may be used, if available).
Laboratory results obtained at the screening visit, meeting the following criteria:
- Serum alanine aminotransferase (ALT) <= 2 times upper limit of normal (ULN)
- Serum aspartate aminotransferase (AST) <= 2 times ULN
- Serum total bilirubin <= 2 times ULN
- Proteinuria < +2 on dipstick analysis
- Serum creatinine <= 1.5 times ULN
- Absolute neutrophil count (ANC) >= 1500 cells/mm3
- Hemoglobin (Hgb) >= 10.0 g/dL
- Platelet count >= 105/mm3
- If the subject is treated with respiratory medications, such as inhaled bronchodilators or inhaled corticosteroids, or other chronic medications for the treatment of the subjects´s other medical condition(s), the subject's medication doses were unchanged for at least 14 days prior to the baseline BAL visit.
Exclusion Criteria:
- Clinically significant pulmonary impairment, other than chronic pulmonary disease (COPD).
- The subject has received any alpha 1 proteinase inhibitor (α1-PI) augmentation therapy (e.g., Prolastin, Zemaira, Aralast, or an investigational α1-PI, by any route including intravenous and inhaled) within 28 days prior to screening.
- The subject has received an investigational drug or device within 1 month prior to screening, or the subject is currently receiving an investigational drug or device. If the subject receives another investigational drug or device after enrollment, the subjects is to be withdrawn from the trial.
- Presence of clinical symptoms of any lower respiratory tract infection or acute pulmonary exacerbation within 14 days prior to screening.
- The subject has a known selective Immunoglobulin A (IgA) deficiency (IgA level less than 15 mg/dL) and/or antibody against IgA.
- The subject is pregnant or lactating, or intends to become pregnant during the course of the study.
- The subject is not a suitable candidate for a BAL procedure.
- Moderate or severe bronchiectasis (total daily sputum production > 10 mL).
- Clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance.
- Prior history of adverse reaction to local anaesthetics, sedatives, pain control drugs, and other medication employed at the study center for perioperative care associated with the BAL procedure.
- Long-term use of oral or parenteral glucocorticosteroid within 28 days prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min
Time Frame: During 8 consecutive weeks of treatment
|
During 8 consecutive weeks of treatment
|
|
Number of Changes in the Rate of Infusion
Time Frame: During 8 consecutive weeks of treatment
|
Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min
|
During 8 consecutive weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median ratio of post- to pre-treatment BAL ELF ANEC levels
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Change in in the Ratio of BAL ELF α1-PI to Human Neutrophil Elastase (HNE) Complex Concentration
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median change in the ratio of BAL ELF α1-PI to HNE complex concentration from baseline to post-treatment
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Change in the α1-PI Plasma Level
Time Frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment
|
Mean change in the plasma level of α1-PI from baseline to post-treatment
|
Blood samples were collected at baseline and after 8 consecutive weeks of treatment
|
Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level
Time Frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment
|
Mean change in the plasma ANEC level from baseline to post-treatment
|
Blood samples were collected at baseline and after 8 consecutive weeks of treatment
|
Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion
Time Frame: During 8 consecutive weeks of infusion
|
Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: ≥ 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to >38°C (>100.4°F).
If the pre-infusion body temperature was already >38°C (>100.4°F),
then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant.
• Respiratory rate: 25% increase above pre-infusion value
|
During 8 consecutive weeks of infusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the BAL ELF Free Neutrophil Elastase Level
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median ratio of post- to pre-treatment BAL ELF IL-8 Level
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Change in the BAL ELF Tumor Necrosis Factor-alpha (TNF-α) From Baseline to Post-treatment
Time Frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Median change in the BAL ELF TNF-α from baseline to post-treatment
|
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2006
Primary Completion (Actual)
December 14, 2007
Study Completion (Actual)
December 14, 2007
Study Registration Dates
First Submitted
November 3, 2006
First Submitted That Met QC Criteria
November 3, 2006
First Posted (Estimate)
November 6, 2006
Study Record Updates
Last Update Posted (Actual)
May 13, 2021
Last Update Submitted That Met QC Criteria
April 17, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Subcutaneous Emphysema
- Emphysema
- Alpha 1-Antitrypsin Deficiency
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Serine Proteinase Inhibitors
- Trypsin Inhibitors
- Protease Inhibitors
- Alpha 1-Antitrypsin
Other Study ID Numbers
- 460502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha 1-Antitrypsin Deficiency
-
Thomayer University HospitalMasaryk UniversityRecruiting
-
University of FloridaAlpha-1 FoundationEnrolling by invitation
-
Grifols Therapeutics LLCCompletedAlpha₁-Antitrypsin DeficiencyUnited States
-
Michael Campos, MDCSL BehringCompletedAlpha 1 Antitrypsin DeficiencyUnited States
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); N... and other collaboratorsTerminatedLiver Cirrhosis | Alpha-1-antitrypsin DeficiencyUnited States
-
Alnylam PharmaceuticalsTerminatedZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseUnited Kingdom
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedAlpha 1 Antitrypsin Deficiency | AATDUnited States
-
Hospices Civils de LyonCompletedChildren With a Deficiency of Alpha-1 AntitrypsinFrance
-
Heidelberg UniversityTerminatedHereditary Emphysema (Alpha 1-antitrypsin Deficiency)Germany
-
Grifols Therapeutics LLCCompletedEmphysema | Alpha 1-antitrypsin Deficiency (AATD)United States
Clinical Trials on Alpha1-Proteinase Inhibitor
-
Grifols Therapeutics LLCTerminatedCOVID-19United States, Brazil, Chile, Colombia, Mexico
-
Baxalta now part of ShireBaxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)CompletedAlpha 1-Antitrypsin DeficiencyAustralia, New Zealand
-
Grifols Therapeutics LLCTerminatedType 1 Diabetes MellitusUnited States
-
Grifols Therapeutics LLCCompletedEmphysema | Alpha 1-antitrypsin Deficiency (AATD)United States
-
ShireWithdrawnChronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireTerminatedChronic Obstructive Pulmonary Disease | Alpha1-antitrypsin DeficiencyUnited States, Canada, Australia
-
TakedaWithdrawnChronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
-
Grifols Therapeutics LLCCompleted
-
CSL BehringCompletedEmphysema | Alpha1-proteinase Inhibitor DeficiencyAustralia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
-
Baxalta now part of ShireCompletedAlpha1-antitrypsin DeficiencyUnited States, Canada